Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MIP Technologies Presents New Range of RENSA™ Industrial Resins

Published: Monday, January 27, 2014
Last Updated: Monday, January 27, 2014
Bookmark and Share
New range of polymeric separation resins for industrial use.

MIP Technologies has presented a new range of RENSA™ industrial resins. The company is now offering industrial resin products together with recently published product- and application notes on the website http://www.biotage.com/product-page/rensa-bulk-resins.

These notes describe the materials and physical properties as well as the performance of the new resins so that customers can select the appropriate resin for their specific separation requirements.

“The food, beverage, pharma, consumer products and life science industries are constantly confronted with new separation challenges as the result of an ever changing regulatory environment and the pressure to achieve a better process economy. In response to this need, MIP Technologies has established a broad range of polymeric materials spanning a wide chemistry landscape that will enable these industries to overcome those separation challenges” says Dr. Ecevit Yilmaz, Product Manager – Industrial Resins.

Dr. Yilmaz continued, “The separation materials can be used by our customers at the pilot and production scale to either extract undesired impurities or to enrich specific target compounds from complex matrices.”

“The area of Industrial Scale applications is an important new pillar in the business of Biotage. We will continue to invest into the development of our Industrial Resin portfolio and we will further expand the range of engineered polymeric adsorbents. This will allow us to offer unique and highly selective separation solutions to our wide range of industrial customers” says Dr. Ecevit Yilmaz.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!